艾迪莎与柳氮磺胺吡啶治疗溃疡性结肠炎的疗效以及安全性比较

Comparision of Etiasa and Salicylazo Sulfapridiniin Treatment of Ulcerative Colitis

目的观察艾迪莎(5-ASA)与柳氮磺胺吡啶(SASP)治疗溃疡性结肠炎(UC)的疗效及安全性。方法将确诊60例溃疡性结肠炎患者随机分为5-ASA组(29例)和SASP组(31例),分别口服艾迪莎和柳氮磺胺吡啶,给药8周。结果 5-ASA组总有效率75.9%,高于SASP组的71.0%,但差异不显著(P>0.05);5-ASA组副反应发生率为10.3%,显著少于SASP组(16.1%)(P<0.05)。结论艾迪莎治疗UC疗效与SASP相似,但副反应显著少于SASP。

Objective To investigate the efficacy and the safety of etiasa（5-ASA） and salicylazo sulfapridini（SASP）in treating ulcerative colitis.Methods 60 patients were divided into 5-ASA group（29 cases） and SASP group（31 cases） and treated with etiasa and salicylazo sulfapridini respectively.Results Compared with SASP group,the total effective patients was not significantly improved（P 0.05）（71.0% VS 75.9%） and the side effect was significant（P0.05）（16.1%VS 10.3%） after 8 weeks.Conclusion Etiasa can treat effectively and safely ulcerative colitis.